Analysts Set Expectations for Quotient Limited’s Q2 2018 Earnings (QTNT)
Quotient Limited (NASDAQ:QTNT) – Analysts at Jefferies Group reduced their Q2 2018 EPS estimates for Quotient Limited in a research note issued to investors on Monday. Jefferies Group analyst B. Couillard now anticipates that the company will post earnings per share of ($0.59) for the quarter, down from their previous forecast of ($0.57). Jefferies Group also issued estimates for Quotient Limited’s Q3 2018 earnings at ($0.63) EPS, Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($2.10) EPS, Q1 2019 earnings at ($0.41) EPS, Q2 2019 earnings at ($0.39) EPS, Q3 2019 earnings at ($0.38) EPS, FY2019 earnings at ($1.15) EPS and FY2020 earnings at ($0.31) EPS.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine raised shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $22.00 price target on shares of Quotient Limited in a report on Tuesday, April 18th.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/10/analysts-set-expectations-for-quotient-limiteds-q2-2018-earnings-qtnt.html.
Shares of Quotient Limited (NASDAQ QTNT) traded down 5.37% during midday trading on Thursday, hitting $5.11. The company’s stock had a trading volume of 32,205 shares. The firm’s market cap is $73.46 million. The stock’s 50 day moving average is $6.39 and its 200-day moving average is $6.70. Quotient Limited has a 52-week low of $3.75 and a 52-week high of $8.64.
Quotient Limited (NASDAQ:QTNT) last issued its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.55). The firm had revenue of $6.83 million for the quarter, compared to the consensus estimate of $5.70 million. Quotient Limited had a negative return on equity of 1,303.22% and a negative net margin of 381.66%.
In related news, insider D J. Paul E. Cowan sold 9,420 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $6.11, for a total value of $57,556.20. Following the transaction, the insider now owns 26,666 shares of the company’s stock, valued at $162,929.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider D J. Paul E. Cowan sold 20,580 shares of the stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $6.29, for a total value of $129,448.20. Following the completion of the transaction, the insider now directly owns 26,666 shares in the company, valued at approximately $167,729.14. The disclosure for this sale can be found here. In the last ninety days, insiders sold 165,612 shares of company stock worth $1,061,671. Insiders own 29.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QTNT. Ameriprise Financial Inc. boosted its position in Quotient Limited by 3.1% in the first quarter. Ameriprise Financial Inc. now owns 1,739,838 shares of the company’s stock worth $12,161,000 after buying an additional 52,761 shares in the last quarter. Nicholas Hoffman & Company LLC. purchased a new position in Quotient Limited during the first quarter worth approximately $150,000. Perceptive Advisors LLC boosted its position in Quotient Limited by 2.2% in the first quarter. Perceptive Advisors LLC now owns 2,917,785 shares of the company’s stock worth $20,372,000 after buying an additional 63,299 shares in the last quarter. FNY Partners Fund LP purchased a new position in Quotient Limited during the first quarter worth approximately $636,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in Quotient Limited during the second quarter worth approximately $341,000. 38.61% of the stock is currently owned by institutional investors and hedge funds.
About Quotient Limited
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.